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Abstract
Background: Development and maintenance of the blood-brain and blood-retinal barrier is critical for the
homeostasis of brain and retinal tissue. Despite decades of research our knowledge of the formation and
maintenance of the blood-brain (BBB) and blood-retinal (BRB) barrier is very limited. We have established an in vivo
model to study the development and maintenance of these barriers by generating a transgenic zebrafish line that
expresses a vitamin D-binding protein fused with enhanced green fluorescent protein (DBP-EGFP) in blood plasma,
as an endogenous tracer.
Results: The temporal establishment of the BBB and BRB was examined using this transgenic line and the results
were compared with that obtained by injection of fluorescent dyes into the sinus venosus of embryos at various
stages of development. We also examined the expression of claudin-5, a component of tight junctions during the
first 4 days of development. We observed that the BBB of zebrafish starts to develop by 3 dpf, with expression of
claudin-5 in the central arteries preceding it at 2 dpf. The hyaloid vasculature in the zebrafish retina develops a
barrier function at 3 dpf, which endows the zebrafish with unique advantages for studying the BRB.
Conclusion: Zebrafish embryos develop BBB and BRB function simultaneously by 3 dpf, which is regulated by tight
junction proteins. The Tg(l-fabp:DBP-EGFP) zebrafish will have great advantages in studying development and
maintenance of the blood-neural barrier, which is a new application for the widely used vertebrate model.
Background
The central nervous system (CNS) has developed specia-
lized “barriers” to isolate neurons from the blood
stream. These barriers are critical for neurological func-
tion, as they maintain a stable environment with the
regulation of ionic balance and nutrient transport and
blockage of potentially toxic molecules. The CNS has
two types of barriers: endothelial and epithelial [1,2].
The blood-retinal barrier (BRB) consists of an inner
BRB, formed by endothelial cells lining the retinal blood
vessels and the outer BRB formed by the retinal pigment
epithelium (RPE), a layer of epithelial cells between the
retina and non-neuronal choroid [2,3]. The blood-brain
barrier (BBB) and the blood-spinal cord barrier are
endothelial barriers located within the cerebral vessels of
the brain and the spinal cord, whereas the barrier
between blood and the cerebrospinal fluid (blood-CSF
barrier) is formed by the epithelial cells of the choroid
plexus [1,2].
Both the endothelial and epithelial barriers have tight
junctions, which seal the intercellular cleft of endothelial
or epithelial cells and restrict paracellular diffusion of
water-soluble molecules[4]. A number of tight junction
proteins have been identified[1,5,6] which include cyto-
plasmic adapter proteins such as zona occludens-1 (ZO-
1), that link trans-membrane proteins such as occludin
and claudins to the cytoskeleton. While occludin and
claudins are tight-junction-specific, ZO-1 is also a com-
ponent of adherens junctions[1,5,6]. Studies on these
proteins have determined that tight-junctions, initially
regarded as static and rigid, are dynamic structures
capable of rapid modulation in response to physiological
or pathological signals. Claudin 5a has been recently
shown to be essential for the establishment of a neuro-
epithelial barrier and zebrafish brain ventricular lumen
expansion[7].
The dearth of knowledge on BBB/BRB development
and disruption is likely due to the fact that BBB/BRB
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mainly on in vitro models of cultured cells and experi-
ments of in situ brain/eye perfusion. An in vivo animal
model, which can be studied without disrupting the
organs, will be critical to address the pathophysiology of
BBB/BRB development. Almost all vertebrates, including
teleosts, have a BBB with similar functional characteris-
tics [8,9]. The teleost zebrafish (Danio rerio)h a sp r o v e n
to be a powerful model system to study mechanisms of
organogenesis [10], including development of the circu-
latory system [10,11]. Recently, Jeong et al [12] have
examined the BBB in zebrafish. Using molecular mar-
kers and injection assays they have demonstrated that a
functional endothelial-based BBB is established as early
as 3 dpf (days post fertilization) [12].
The characteristics of the BRB, including the molecu-
lar and cellular components, development, maintenance
and function have not been studied as extensively, but
are believed to be very similar to the BBB. Increased
vascular permeability and breakdown of the BRB under-
lies the vision loss in diseases such as retinopathy of
prematurity, diabetic retinopathy and age-related macu-
lar degeneration [3]. Although a number of studies have
suggested a role for tight junction or adherens junction
[13] proteins such as occludin[13-15], claudin-5[16],
ZO-1[17,18] and VE-cadherin[19-21] in the maintenance
of the BRB, our understanding of the molecular
mechanisms contributing to the BRB breakdown in
pathological conditions is incomplete.
Because of its tissue transparency and rapid develop-
ment, we hypothesized that the zebrafish would be a
good model system to examine the molecular mechan-
isms regulating the development and maintenance of
the BRB. We have determined that the embryos of zeb-
rafish develop a functional BRB in the hyaloid vessels by
3 dpf. We have generated a transgenic zebrafish line
that can display the formation, disruption and recon-
struction of the BBB and BRB in vivo.I tw i l lh a v eg r e a t
advantages in studying the blood-neural barrier through
forward-genetic screens and reverse-genetic techniques.
Results
The Blood Retinal Barrier (BRB) and Blood Brain Barrier
(BBB) is established at 3 dpf in zebrafish
To determine the temporal sequence of establishment of
the BRB and BBB in zebrafish, we injected two fluores-
cent dyes into the circulatory system of Tg(flk1:mCherry)
[22,23] embryos at 2 dpf, 2.5 dpf and 3 dpf. The vascu-
lature of flk1:mCherry embryos is labeled with a red
fluorescent protein, mCherry. Two tracers were utilized
for this purpose, fluorescein dextran 4 (FD4-4000 Da),
to detect large molecule diffusion and sodium fluores-
cein (376 Da), a small molecule tracer used as a marker
of vascular permeability in routine clinical practice.
We observed that the BRB in hyaloid vessels was
established in 3-day (3 dpf) embryos, which could retain
FD4 in the hyaloid vasculature (Fig. 1E&1F), in contrast
to the vessels in 2 and 2.5 dpf embryos, which could not
(Fig. 1A-D). Interestingly, FD4 leakage from the trunk
vessels of 3 dpf embryos occurred immediately after
injection. No FD4 was present in the trunk vessels at 30
minutes after injection, being diffused over the entire
trunk with some dye accumulation in the myotomal
boundaries (arrowhead in Fig. 1K), and minimal FD4 in
the intersegmental vessels (arrows in Fig. 1K&1L). In
addition, we examined the permeability of the brain vas-
culature, particularly the central arteries such as middle
mesencephalic central artery (MMCtA), posterior
mesencephalic central artery (PMCtA), and cerebellar
central artery (CCtA). In the 2dpf and 2.5dpf embryos,
although we observed some dye leakage over time with
accumulation mostly in the brain ventricles (arrowheads
in Fig. 1G-J), the boundaries of the FD4-infused
MMCtA (arrows in Fig. 1G-J) and CCtA (blue arrows in
Fig. 1G-J) remained sharp and clear at 50 or even 150
minutes after injection, indicating that the endothelial
barrier against FD4 is established in the central arteries
at 2 dpf.
In contrast to FD4, most of the leaked sodium-fluores-
cein did not accumulate in the brain ventricles (arrow-
heads in Fig. 1M&1N), but diffused evenly throughout
t h ee n t i r eb r a i n( F i g .1 M - P). In the 2.5 dpf embryos,
after 30 minutes of injection, the boundaries of the cen-
tral arteries could not be differentiated from adjacent
brain tissue (arrows, blue arrows and asterisks in Fig.
1M&1N). In 3 dpf embryos, although the diffusing fluor-
escein caused an increased background throughout the
brain, the boundaries of the central arteries remained
sharp and clear at 50 minutes after injection (arrows,
blue arrows and asterisks in Fig. 1O&1P), suggesting
that the endothelial barrier against fluorescein has been
established in the vessels. Similar observations were
made in the retina, which suggests that the BRB against
small molecules is formed in the hyaloid vasculature at
3 dpf as well (Fig. 1Q&1R).
Claudin-5 is a marker for the CNS vasculature
Claudin-5 is a tight-junction protein expressed in the
BBB. We used a monoclonal antibody against the
C-terminal region of mouse claudin-5, to examine
the spatial expression of claudin-5 in the zebrafish CNS
vasculature. The antibody used in these experiments was
raised against the 20-residue peptide of the C-terminal
region of mouse claudin-5, which has a similar sequence
to two zebrafish claudin-5 genes.
We observed that the claudin-5 signal co-localizes
with EGFP expressing endothelial cells of the hyaloid
and brain vasculature (Fig. 2C&2D), but not of the
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Page 2 of 14Figure 1 Development of the BRB and BBB in zebrafish. FD4 (4,000 Da, green) was injected to the sinus venosus of Tg(flk1:mCherry) embryos
at 2 dpf (A, B, G, H), 2.5 dpf (C, D, I, J) and 3 dpf (E, F, K. L). Live confocal images of the hyaloid vessels (A-F, side view), brain vessels (G-J, dorsal
view) and trunk vessels (K-L, side view) were obtained from 10 to 150 minutes after injection. Insets and panel L are images of established
vasculature of the injected embryos (red). In the brain, boundaries of the middle mesencephalic central artery (MMCtA) are indicated by arrows
in G-J, cerebellar central artery (CCtA), by blue arrows in G-J and posterior mesencephalic central artery (PMCtA) by asterisks in I&J. Arrows in K&L
indicate intersegmental vessels and arrowhead in K shows the myotomal boundaries. A small molecule, fluorescein (376 Da, green), was also
used as a tracer in the injection assay (M-R). In the 2.5 dpf embryos (M&N), the PMCtA (asterisk) could not be differentiated, and boundaries of
MMCtA (arrows) and CCtA (blue arrows) were enlarged and became blurred 30 minutes after injection. However in the 3 dpf embryos injected
with fluorescein (O-R), boundaries of the MMCtA (arrows), PMCtA (asterisk), CCtA (blue arrows) and the hyaloid vessels (Q&R) remained sharp and
clear after 50 minutes of injection. The leaked FD4 accumulated mostly in brain ventricles (arrowheads in G-J). In contrast, most of the leaked
fluorescein did not accumulated in the brain ventricle (arrowheads in M&N), but evenly diffused throughout the brain (M-P). Scale bars: 50 um.
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Page 3 of 14trunk vessels (Fig. 2B). The 1st to 4th branchial arches
(shaded arrows in Fig. 2E) and the anterior pronephros
(shaded arrowhead in Fig. 2D) express claudin. These
results demonstrate that the mouse claudin-5 antibody
i sag o o dm a r k e rf o rt h eB B Ba n dB R Bo fz e b r a f i s h .A t
3 dpf, claudin-5 immunoreactivity is present in the hya-
loid (Fig. 2C&2C’) and brain vasculature (Fig. 2D&2D’)
but not in the trunk vessels (Fig. 2B&2B’). Panels B-D
and B’-D’ are enlarged views of the dashed squares in A
and A’.( F i g .2 D & 2 D ’) The claudin-5 antibody binds to
the central artery (bracket) and the primordial hindbrain
channel (PHBC, arrow). Besides the CNS vasculature,
claudin-5 is also present in the 1st to 4th branchial
arches (shaded arrows in Fig. 2E&2E’) and the anterior
pronephros (shaded arrowhead in Fig. 2D) that is loca-
lized near the 4th branchial arch (shaded arrow in Fig.
2D). The polygonal RPE cells (arrow) and epithelial cells
in the third (arrowhead) and the fourth ventricles (blue
arrows) as well as the mid plane of the brain (shaded
arrowhead) have a strong claudin-5 signal (Fig. 2F&2G,
merged red and green images).
Expression of claudin-5 in the developing BBB
Temporal expression of claudin-5 was evaluated in the
developing BBB. Four pairs of central arteries that
develop via angiogenesis, sprout into brain parenchyma
as early as 2dpf [24]. At 2 dpf (Fig. 2H&2H’), the
MMCtA (arrows) and CCtA (blue arrows), two pairs of
newly developed central arteries, express claudin-5 while
the basal communicating artery (BCA, shaded arrow-
head) that had developed during the earlier vasculogen-
esis stage does not express claudin-5 (Fig. 2I &2I’;2 J
&2J’). Starting at 2.5 dpf, vessels that have developed
during the vasculogenesis stage start to express claudin-
5. This includes the middle cerebral vein (MCeV)
(shaded arrows in Fig. 2I) in the top layer and the BCA
Figure 2 Spatial and temporal expression of claudin-5 in the developing BBB. Tg(flk1:EGFP) embryos at 2 dpf, 2.5 dpf, and 3 dpf were
stained with a monoclonal claudin-5 antibody. Confocal images of whole mount embryos were analyzed for claudin-5 expression (red) (A-E and
H-M; Alexa Fluor 568 labeled secondary antibody) in developing blood vessels (green) (A’-E’ and H’-M’; EGFP labeled vascular endothelial cells;
F&G, merged pictures). All the samples are oriented with anterior to the left. A-E and A’-E’, lateral views; other panels, dorsal views. Scale bars: 50
um.
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Page 4 of 14(shaded arrowhead in Fig. 2J) in the upper middle layer
of the head. The intensity of staining in blood vessels
that develop via angiogenesis after 2 dpf such as
MMCtA (arrows) and CCtA (blue arrows), increases
over time. Like the mesencephalic vein (MsV, arrow-
heads), all the vessels in the top layer show the claudin-
5 signal, although some only have a weak staining, such
as the anterior cerebral vein (ACeV, blue arrowheads).
(Fig. 2K-M, K’-M’). At 3 dpf, all the brain vessels
express claudin-5. The spatial and temporal expression
of claudin-5 is consistent with our results with leakage
of injected dyes as well as those described previously
[12] in that the zebrafish BBB is fully developed by 3
dpf. This result also suggests that claudin-5 expression
is a useful marker for the development of the zebrafish
BBB.
Expression of claudin-5 in the developing BRB
A claudin-5 signal is present at 3 dpf in the hyaloid vas-
culature of zebrafish (Fig. 2C) consistent with the pre-
sence of a vascular barrier. We further analyzed the
temporal distribution of claudin-5 protein from 2 to 4
dpf, at which time the BRB is being established (Fig. 1).
We found claudin-5 to be present in the net of the hya-
loid vasculature (HV; arrows in Fig. 3B&3B’)a n dt h e
hyaloid artery (HA) as early as 2.5 dpf, with a cone
shaped localization (H-shape line in Fig. 3B), with a dia-
meter wider than that of the hyaloid artery (asterisk in
Fig. 3B’). At 3 dpf, the intensity of the claudin-5 signal
is increased in the hyaloid vasculature (arrow in Fig.
3C). At this time claudin-5 signal appears in the inner
plexiform layer (shaded arrowhead in Fig. 3C). Claudin-
5 in the hyaloid artery appears as a line within the
cone-shape staining until 3.5 dpf, after which it overlaps
with endothelial cell staining in the hyaloid artery (aster-
isks in Fig. 3C&3D). At 4 dpf, claudin-5 staining is
found at the points of penetration of the hyaloid artery
into the retina (arrow in Fig. 3I). Overall, the hyaloid
vessels, hyaloid artery and the vessel connecting the hya-
loid vessels and the inner optic circle (IOC), but not the
IOC itself and other choroidal vessels, express claudin-5
(Fig. 3J). As indicated by the expression of claudin-5 in
the RPE cells, the outer BRB is also formed at 3 dpf
(Fig. 3E&3F). The expression pattern of claudin-5 in the
eye correlated with the observation that the BRB is
formed at 3 dpf in zebrafish (Fig. 1).
We also examined the spatial and temporal distribu-
tion of ZO-1, a molecular component of both tight
junctions and adherens junctions. We observed that
ZO-1 was expressed earlier than claudin-5 in the BRB
and BBB (see Additional file 1). ZO-1 is not specific to
the CNS vasculature, since the ZO-1 antibody binds to
a number of endothelial vessels outside of the CNS,
such as the intersegmental vessels (see Additional file 1).
Claudin-5a and 5b are expressed in the hyaloid
vasculature
Based on the sequence of the peptide used in generating
the mouse claudin-5 antibody, we examined the spatial
and temporal expression of five zebrafish claudin genes
from 1 to 4 dpf. Claudin-5a, claudin-5b and claudin-h
have the highest homology at the C-termini (Fig. 4, A).
Claudin-5a was expressed in the CNS (midbrain, hind-
brain, epiphysis ventricle zones and retina), from 1-2
dpf, which is in accordance with online data (ZFIN ID:
ZDB-PUB-040907-1, http://www.zfin.org). Claudin-5a
mRNA was also present in the hyaloid vasculature from
1.5 to 2.5 dpf (black and white arrows in Fig 4, C-E
&4C’-E’). At 3 dpf, it could still be detected in the hya-
loid vessels albeit at low levels (data not shown). mRNA
of claudin-5b was expressed throughout the vasculature
system at 1 dpf (Fig 4, F), then gradually lost at 2 dpf,
except in the blood vessels of the brain and cardiovascu-
lar system (arrows and arrowhead in Fig 4, G). This is in
agreement with the gene expression data available
through the Zebrafish Information Network (ZFIN ID:
ZDB-PUB-040907-1, http://www.zfin.org). Here we
extend this study to demonstrate expression of claudin-
5b in the hyaloid vessels from 1.5 to 3 dpf (Fig 4, H),
similar to claudin-5a. The partially overlapped expres-
sion patterns, as revealed by in situ hybridization and
immunohistochemistry (Fig. 2, 3 &4), suggest that the
anti-mammalian claudin-5 antibody can recognize both
claudin-5a and claudin-5b isoforms that constitute the
zebrafish BRB and BBB. In situ hybridization experi-
ments with zebrafish claudin h gene as well as two
negative (sense) controls for cldn 5a and cldn5b showed
no expression in the hyaloid vasculature around the lens
(see Additional file 2). We have also used a 5.6 kb DNA
fragment, upstream of the coding sequence of the clau-
din-5b to drive expression of EGFP and determined
expression in the hyaloid vessels (see Additional file 3).
Both these approaches suggest that claudin 5a and 5b
are present in the hyaloid vasculature. No expression of
the other three zebrafish claudin genes (claudin-h, clau-
din-k and claudin-1) was detected in the blood vessels
of the brain and the hyaloid vessels (data not shown).
The BRB can be visualized in Tg(l-fabp:DBP-EGFP)
zebrafish
In order to visualize the blood retinal barrier and blood-
brain barrier in vivo, we generated transgenic lines of
zebrafish that express a vitamin D-binding protein fused
with the enhanced green fluorescent protein (DBP-
EGFP) under the control of the liver-type fatty acid
binding protein (l-fabp) promoter. Our goal was to gen-
erate a transgenic line that expresses a fusion protein in
the plasma that could be used as an endogenous tracer
for BBB or BRB breakdown. The l-fabp promoter can
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hood [25]. DBP is a member of the albumin family and
in wild type zebrafish, is translated in the hepatic cells
and secreted into the blood circulation. By using the l-
fabp promoter and the DBP-EGFP, we generated a
transgenic line that expresses the fusion protein in the
plasma as an endogenous tracer.
The BBB and BRB in Tg(l-fabp:DBP-EGFP) can be dis-
played from 3 dpf to two months (Fig. 5).
The presence of EGFP fluorescence in all eggs laid by
the l-fabp:DBP-EGFP transgenic fish (Fig. 5A), indicates
that the DBP-EGFP is stored in oocytes as maternal
material. At 1.5 dpf, the DBP-EGFP is expressed at low
levels and the protein accumulates mostly in the brain
ventricles (arrowheads in Fig. 5B) and area of the heart
(arrow in Fig. 5B). At 2 dpf, there is a diffuse localiza-
tion of EGFP in the eye indicating leakage of DBP-EGFP
out of the HV (arrowhead in Fig. 5C’). In the brain the
Figure 3 Spatial and temporal expression of claudin-5 in the developing BRB. Tg(flk1:EGFP) embryos and larvae from 2 dpf to 4 dpf were
stained with mouse anti-claudin-5. Confocal images of whole mount were analyzed for claudin-5 (red) (A-I; Alexa Fluor 568) expression in
hyaloid blood vessels (green) (A’-D’ and G’-I’; EGFP). All the panels are dorsal views except G&G’. The claudin-5 signal in the hyaloid vessels at 2
dpf (A&A’) is minimal. At 2.5 dpf (B&B’), and 3 dpf (C&C’) the staining in the hyaloid vasculature is increased. Claudin-5 is also expressed in the
hyaloid artery (asterisks) and outer limiting membrane of the retina (shaded arrow) and inner plexiform layer (shaded arrowhead). (D&D’) At 3.5
dpf, the wider cone-shape staining is lost and the claudin-5 signal overlaps completely with the HA (asterisks). The vessel connecting the HV and
the inner optic circle (IOC) also has a strong claudin-5 signal (blue arrows in D&D’, G&G’). (E&F) In the retina, the claudin-5 signal does not clearly
outline the polygonal RPE (arrow) until 3 dpf. The insert is an enlarged view of the dashed square. At 4 dpf (G-I), the HV (arrows in G&G’, H&H’)
and the HA, but not the choroidal vasculature (such as the IOC, indicated by arrowhead in G’), express claudin-5. The claudin-5 is also expressed
around the foramen (opening) through which the HA penetrates the retina (arrow in I). The panel J is a schematic illustrating expression of
claudin-5 in optic vasculature of zebrafish. Scale bars: 50 um.
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Page 6 of 14Figure 4 Claudin-5a and 5b expression in hyaloid vasculature. (A) The 3’ ends of three zebrafish claudin genes have significant homology
with the C-terminal of mouse claudin-5. Claudin-5a (zgc 85723; GenBank: NM_213274) and claudin-5b (zgc 103419; GenBank: NM_001006044)
are mostly homologous to claudin-5a of Fugu rubripes, with 82% identical (plus 8% similar) and 75% identical (plus 14% similar) amino acid
sequences, respectively. The zebrafish claudin-h (GenBank: NM_131767) is mostly homologous to claudin-3a of Fugu. (B-E’) Whole mount in situ
hybridization of claudin-5a expression. (B) Claudin-5a is expressed in the CNS (midbrain, hindbrain, ventricular zone, and epiphysis) at 1 dpf. (C-E
&C ’-E’) From 1.5 to 2.5 dpf, claudin-5mRNA is detected in the hyaloid vasculature (black arrows), hyaloid artery (white arrows) and the cornea
(arrow heads). (F-H) Claudin-5b is expressed in the entire vascular system at 1 dpf (arrow and arrowheads in F), and is confined to the blood
vessels of the brain (arrows in G) and cardiovascular system (arrowhead in G) at 2 dpf. Similar to claudin-5a, expression of claudin-5b in the
hyaloid vasculature (black arrow in H) and hyaloid artery (white arrow in H) is seen at 1.5 dpf and lasts till 3 dpf. B-E, dorsal view; C’-E’, side view;
F-H, side view.
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Page 7 of 14Figure 5 Expression pattern of DBP-EGFP in the blood plasma of l-fabp:DBP-EGFP transgenic zebrafish. Images were obtained from Tg(l-
fabp:DBP-EGFP;flk1:mCherry) fish to visualize DBP-EGFP (green) and endothelial cells lining blood vessels (red)(mCherry). The fish were oriented
with anterior to the left. All panels are side views except E. (A) green fluorescence in eggs laid by female Tg(l-fabp:DBP-EGFP) fish. (B) DBP-EGFP
expression at 1.5 dpf. (C, C’, D & E) DBP-EGFP expression at 2 dpf. The central arteries (arrows) are the first distinguishable blood vessels. (F, F’,G
& H) DBP-EGFP expression at 60 hpf. The dashed rectangles in H and K are merged pictures of red and green channels. The branchial arches
(blue arrow) can be differentiated at the time, but boundaries of HV are still not clear (arrowhead). At 3 dpf (I, I’, J & K), the boundaries of the HV
become sharp (arrows in I&I’). More vessels appear in the liver (dashed rectangle) and more brain vessels can be seen (arrows in G and J). At 4
dpf (L, L’, M & N), the EGFP-infused hyaloid and brain vessels can be easily differentiated from the fluorescent background (arrows in L, L’ and
M), as can the intersegmental vessels (arrow in N) and the dorsal aorta (blue arrow). Accumulation of DBP-EGFP in the myotomal boundaries
(arrowhead) (N) is observed from leakage out of the vasculature. At 5 dpf (O), the HV (blue arrow) and the trunk vessels (arrow) are
distinguishable, but the brain vessels are not (arrowhead), due to the increased fluorescent background in the brain. (P) At 60 dpf, the HV is still
distinguishable.
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able blood vessels (arrows in Fig. 5D&5E). At 60 hpf,
blood vessels begin to grow into the liver (Fig. 5H) and
the branchial arches (blue arrow in Fig. 5G) become dis-
tinguishable, but the boundaries of the HV are not
sharp until 3 dpf (Fig. 5F, F’,Ia n d5 I ’). At 4 dpf, the
EGFP-infused hyaloid and brain vessels as well as the
intersegmental vessels and the dorsal aorta (arrows and
the blue arrow in Fig. 5L-N) can be easily differentiated
from the fluorescent background. However the bound-
aries of the blood vessels in the trunk are not as sharp
and distinct (Fig. 5N&5O), as those of the hyaloid and
the brain vessels (arrows in Fig. 5L-M). After 5 dpf, the
increased fluorescence background in the brain prevents
visualization of the brain vasculature (arrowhead in Fig.
5O), but the HV remains distinguishable in the fish up
to 60 dpf (Fig. 5P).
Bradykinin can disrupt the BRB of zebrafish
In an effort to determine if l-fabp:DBP-EGFP transgenic
fish would be a useful tool to screen for inducers and/or
inhibitors of the BRB, we examined the ability of brady-
kinin to induce leakage of EGFP. Bradykinin (BK) is an
oligopeptide hormone that can cause BRB breakdown in
vivo [26]. Extracellular carbonic anhydrase increases ret-
inal vascular permeability through the prekallikrein-
kinin pathway[27,28]. Double transgenic l-fabp:DBP-
EGFP;flk1:mCherry larvae were treated with 8 to 100
μM BK from 5 to 9 dpf. Leaky hyaloid vessels were
identified in 31%, 13% and 7% of the 100 μM-, 50 μM-
and 20 μM-treated larvae respectively, but in none of
the control or 8 μM-treated samples (Fig. 6A,B). In a
separate experiment, flK1:EGFP larvae were stained with
the claudin-5 antibody after treatment with 100 μM BK.
Claudin 5 expression was lost in the hyaloid vasculature
of 36% of the larvae (Fig. 6 C, D). The apparently nor-
mal morphology of the retinal vasculature as visualized
by the red fluorescence (flk:mcherry), suggests the
absence of generalized vascular pathology with bradyki-
nin which likely has specific effects on the barrier func-
tion of the retinal vessels. In addition, direct injection of
bradykinin (2 nL of 20 uM bradykinin) into the eyes of
l-fabp:DBP-EGFP;flk1:mCherry fish resulted in leakage
of DBP-EGFP out of the hyaloid vasculature in 90% of
injected eyes (n = 20) with no effect in the contralateral
control injected eyes (see Additional file 4).
Figure 6 Bradykinin mediated disruption of zebrafish BRB (A, A’ &B ) .T h el-fabp:DBP-EGFP;flk1:mCherry double transgenic larvae were
treated with 8 to 100 μM BK from 5 to 9 dpf. (A) DBP-EGFP (green) in hyaloid vessels of control (left panel), leaky hyaloid vessels (middle and
right panel); (A’) endothelial lining of blood vessels, mCherry (red). (B) At 9 dpf, the larvae were scored for the presence of leaky hyaloid vessels.
Both Fisher’s test and chi-square test indicate that the BK treatment results in significantly increased numbers of larvae showing GFP leakage
compared with those treated with control buffer (P < 0.001). (C) Claudin-5 expression (red) was evaluated by whole mount
immunohistochemistry in Tg(flk1:EGFP) larvae exposed to 100 μM BK and scored as strong expression (left panel), detectable (middle panel) and
undetectable (right panel); (C’) endothelial lining of blood vessels, flk1:EGFP (green). (D) Approximately 47 BK treated and 46 untreated flk1:EGFP
larvae were evaluated for claudin-5 expression in the hyaloid vasculature.
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Disruption of the BBB or BRB is a crucial event in the
development and progression of a number of diseases.
Loss of barrier function leading to increased vascular
permeability in the brain or retina can be a cause or
consequence of the pathology. A detailed understanding
of the physiological processes involved in the develop-
ment and maintenance of the blood-neural barrier is cri-
tical for the identification of therapeutic targets. One of
the major limitations in this regard has been the
absence of an easily regulated in vivo system that allows
alterations of these barriers. The BBB and BRB, initially
regarded as static and rigid, have now been proven to
be dynamic structures with both paracellular and trans-
cellular pathways capable of rapid modulation in
response to physiological or pathological signals [1,29].
Development of the vascular system in the brain can
be classified into three phases: vasculogenesis, angio-
genesis and BBB formation. During brain angiogenesis,
sprouting vessels from the perineural plexus grow into
the proliferating neuroectoderm and form a capillary
network. At this time, the vessels appear to be perme-
able to small molecules [30-33] but not to plasma pro-
teins [31,34]. Although there have been a large number
of studies examining the molecular mechanisms
involved in vasculogenesis and angiogenesis, very lim-
ited information is available for the development of the
BBB [35-38]. The Src-suppressed C kinase substrate is
a factor induced by high oxygen tension. Its expression
in brain astrocytes leads to decreased vascular
endothelial growth factor (VEGF) and increased angio-
poietin-1 secretion, which have been suggested to be
important for the cessation of brain angiogenesis and
formation of the BBB [36]. More recent reports
demonstrate that Wnt signaling is required for CNS
angiogenesis [35] and may play a role in the initiation
of the development of the BBB in mice [37,38].
Hypoxia has been shown to regulate the barrier func-
tion of neural blood vessels by reducing the expression
of claudin 5 in endothelial cells [16]. In addition, clau-
d i n - 5d e f i c i e n tm i c es h o was i z es e l e c t i v e( < 8 0 0D a )
loosening of the blood-brain barrier[39].
In this report we describe l-fabp:DBP-EGFP transgenic
zebrafish, in which the BBB and BRB can be visualized.
T h i sm o d e lw i l lb eac r i t i c a lt o o lf o rf u t u r es t u d i e s
related to the study of blood-neural barrier development
and differentiation. The molecular weight of the DBP-
EGFP fusion protein, both calculated by the MacVector
software and estimated by Western blot data (see Addi-
tional file 5), is 78 kDa. Since the zebrafish claudin-5a
and claudin-5b are sufficient to block paracellular trans-
port of any molecule of 4000 Da or larger, but not suffi-
cient to block the passage of smaller molecules like
s o d i u mf l u o r e s c e i n( 3 7 6D a )i ti sl i k e l yt h a tD B P - E G F P
would be comparable to high MW compounds.
Human albumin (67 kDa) has been used as an endo-
genous tracer for blood-brain barrier studies and as an
indicator of compromised BBB function in a number of
pathophysiological conditions. Under physiological con-
ditions albumin crosses endothelial cell wall via transcy-
tosis. However, paracellular transport of albumin in
various sized microvessels has been observed under
inflammatory conditions and following treatment with
reagents that affect the integrity of tight-junctions. The
zebrafish DBP is a member of albumin family and is
highly homologous to the human DBP and thus a good
marker to evaluate the integrity of the BBB and BRB.
We have recently demonstrated that knock-down of
claudin-5a results in the leakage of DBP-EGFP out of
the hyaloid vessels (see Additional file 6). These results
taken together with the results in Fig. 6, suggest that
DBP-EGFP, as an endogenous tracer, may be useful to
evaluate the breakdown of the BRB against high molecu-
lar weight compounds, either due to developmental
defects or pathological conditions.
Although the structures of the BBB and BRB in verte-
brates have been fairly well characterized [1-6], informa-
tion about their development during embryogenesis and
their maintenance in adults is limited. Similarities
between them suggest that some of the developmental
and regulatory mechanisms involved in these two barrier
systems may overlap. Many CNS disorders, such as
brain tumors, stroke, trauma, multiple sclerosis and neu-
rodegenerative diseases, are associated with a dysfunc-
tion of the BBB[1,3]. On the other hand, the presence of
the BBB presents a major challenge for delivery of thera-
peutic compounds to the brain, as most drugs do not
cross the BBB [2,40].
I nt h ep r e s e n ts t u d yw eu s e dF D 4a sat r a c e ro fl a r g e
molecular weight and fluorescein as a small molecular
weight tracer. In zebrafish, FD4 (4,000 Da) but not
fluorecein (376 Da) could be retained in the vasculature
at 2 dpf when the central arteries started to express
claudin-5. This suggests that claudin-5 is likely to be cri-
tical for the barrier against large molecules and some
additional junction protein may be needed for the bar-
rier against small molecules. Our results with tracer
injections, the claudin-5 antibody staining, as well as the
observations on the l-fabp:DBP-EGFP embryos, revealed
a subtle difference between the formation of BRB and
BBB. The BRB against both large and small molecules
developed gradually in the hyaloid vessels and was
formed by 3 dpf, similar to the BBB against small mole-
cules. In contrast the BBB against large molecules is
formed in the central arteries at 2 dpf (Fig. 7), and in
other blood vessels at 2.5 dpf. The developmental
Xie et al. BMC Developmental Biology 2010, 10:76
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Page 10 of 14process of the zebrafish BBB is similar to results
obtained from other previously studied vertebrates, in
that the brain vessels of the angiogenesis stage are
permeable to small molecules but not to plasma pro-
teins [31,34].
However, not all cerebral blood vessels are imperme-
able in adult zebrafish. The blood vessels of the circum-
ventriclar organ lack a BBB structure [12,41], as these
vessels have special physiological functions. Consistent
with this, the accumulation of EGFP in the brain of the
l-fabp:DBP-EGFP larvae results in a high fluorescent
background and the brain vasculature becomes indistin-
guishable from 5 dpf onward. Thus the l-fabp:DBP-
EGFP will need to be modified to allow conditional
expression of DBP-EGFP for studies on the BBB of zeb-
rafish post 5 dpf. In contrast, the zebrafish BRB is easier
to evaluate as all the hyaloid vessels develop an inner
BRB structure at 3 dpf; the outer BRB also matures at 3
dpf and further seals off the eyes. This is an added
advantage in studying the BRB as the hyaloid/retinal
vessels can be observed in the transgenic l-fabp:DBP-
EGFP zebrafish up to 60 dpf.
The zebrafish has been widely used to study eye devel-
opment and disease [42], but the BRB has not been stu-
died in this model. Alvarez et al [43] have recently
examined the morphology and development of the hya-
loid and retinal vasculature in zebrafish and identified
an important distinction between mammals and zebra-
fish. In mammals, the regression of the hyaloid vascula-
ture by apoptosis and the formation of the retinal
vasculature by angiogenesis are synchronized processes,
while in the zebrafish, the hyaloid vessels develop into
retinal vessels without regression. In addition, adult zeb-
rafish have tight-junctions in retinal endothelial cells
and pericytes along the retinal vessels[44].
Bradykinin is an oligopeptide hormone derived from
proteolysis of kininogen and is involved in smooth mus-
cle contraction and relaxation, increased vascular per-
meability, activation of pain sensory fibers, hypotension
and inflammation [45]. Bradykinin activates two specific
membrane receptors, B1 and B2 and plays a direct role
in diabetes-induced breakdown of the BRB [26-28]. The
kininogen and two BK receptors have been identified in
zebrafish and two species of the pufferfish [46] and
shown to be localized to the brain and eye [47]. The
structure of BK is evolutionarily conserved between zeb-
rafish and mouse with only two out of ten amino acids
being substituted [48]. Previous studies have determined
that mammalian BK has 16% potency of zebrafish BK in
vitro assays [48]. Although the zebrafish BK receptor B1
is thought to have a ligand-interaction profile distinct
from mammalian BK receptors [48], we observed that
31% of the zebrafish larvae treated with 100 μMm a m -
malian BK for four days demonstrated leaky hyaloid ves-
sels. These findings lend credence to the hypothesis that
t h er e g u l a t o r ym e c h a n i s m so fB R Bm a yb ec o n s e r v e d
between zebrafish and humans.
The use of zebrafish as a model organism to study the
BBB and BRB has a number of advantages. The ability
to carry out forward-genetic screens in zebrafish is one
of the models most attractive features. A forward-
genetic approach following mutagenesis of l-fabp:DBP-
EGFP transgenic zebrafish, and screening for a leaky
BRB phenotype will identify and characterize zebrafish
mutants that affect the establishment and maintenance
of the BRB. This phenotype-driven genome-wide screen,
which makes no assumptions about the genes involved
in the biological processes of interest, can likely reveal
novel genetic pathways involved in the development of
BRB.
Conclusions
We have demonstrated that zebrafish have a BBB and
BRB structure which is formed at 3 dpf. A transgenic
zebrafish line, as well as a monoclonal claudin-5 anti-
body, can display the formation, disruption and
Figure 7 Schematic illustration of endothelial tight junctions
and claudin-5 expression in retinal and brain vasculature of
zebrafish embryos at 2 dpf and 3 dpf. Four pairs of the central
artery express claudin-5 at 2 dpf (red). The figure was adapted from
the online data of Dr. Brant Weinstein’s lab (zfish.nichd.nih.gov/
zfatlas). AMCtA: anterior mesencephalic central artery; MMCtA:
middle mesencephalic central artery; PMCtA: posterior
mesencephalic central artery; CCtA: cerebellar central artery.
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Page 11 of 14reconstruction of the BBB and BRB. The l-fabp:DBP-
EGFP transgenic zebrafish will have great advantages in
identifying the genes involved in development and main-
tenance of the BRB, through reverse-genetic techniques
and forward-genetic screens. Disruption of BRB by bra-
dykinin demonstrates that the transgenic zebrafish could
also be used for experimental testing of therapeutic
agents that could potentially be effective in the treat-
ment of retinal or brain vascular leakage.
Methods
Zebrafish maintenance and strains
All Zebrafish (Danio rerio) studies were conducted in
accordance with the Animal Care and use Committee
guidelines of the Cleveland Clinic (ARC 08498). Zebra-
fish were maintained at 28.5°C on a 14-hour light/10-
hour dark cycle according to standard procedures [49].
Embryos were obtained from natural spawning and
raised at 28.5°C. Tg(flk1:EGFP) and Tg(flk1:mCherry)
lines were a generous gift from the laboratory of Dr.
Stainer [23]. Some embryos were treated with 0.1 mM
1-phenyl-2-thiourea (PTU, Sigma P5272) to inhibit pig-
ment formation. No difference in experimental results
was observed between PTU-treated and untreated
embryos.
Leakage assay by FD4 and fluorescein injections
FD4 (Sigma, 4,000 Da) and fluorescein sodium (Sigma
F6337, 376 Da) were dissolved in embryo medium[49]
to final concentrations of 2 mg/ml and 0.1 mg/ml
respectively. Tg(flk1:mCherry) embryos were anesthe-
tized with 0.2 mg/ml Tricaine (Sigma A5040) at 2 dpf,
60 hpf (hours post fertilization) or 3 dpf. About 3 nl of
FD4 or fluorescein were injected to the sinus venosus.
Following injection, the embryos were mounted in 1%
low-melting agarose and images were taken from 10 to
90 minutes post injection with a confocal microscope
(Leica TCS-SP2).
Whole-mount immunohistochemical staining
Tg(flk1:EGFP) embryos or larvae were fixed with 4% par-
aformaldehyde for 3 hours at 4°C. After washes in 1×
PBS, the samples were digested with 0.125% Trypsin
(Invitrogen) for 11 to 16 minutes at room temperature,
depending on the developmental stages. The samples
were incubated in a blocking solution (1% BSA/3% nor-
mal goat serum/0.4% Triton X-100/1× PBS) with mouse
anti-claudin-5 (Zymed 18-7364, 1:2000) or rabbit anti-
ZO-1 (Zymed 61-7300, 1:4000) at 4°C for 8 hours. After
thorough washes with 0.4% Triton X-100/1× PBS, the
samples were incubated in the blocking solution with
the appropriate secondary antibody, Alexa Fluor 568
goat anti-mouse IgG (Invitrogen, 1:2500) or Alexa Fluor
568 goat anti-rabbit IgG (Invitrogen, 1:3000), at room
temperature for 1 hour. Confocal mages were taken
with the samples mounted in 1% low-melting agarose
(Leica TCS-SP2). The vascular nomenclature is labeled
according to Isogai et al. [24].
Whole-mount in situ hybridization
The coding sequences of zebrafish claudin-5a (648bp;
GenBank: NM_213274) and claudin-5b (654 bp; Gen-
Bank: NM_001006044) were cloned into pCRII-TOPO
and the resulting plasmids were linearized with BamHI
or XhoI for synthesis of antisense or sense probes.
Whole-mount in situ hybridization was performed using
digoxigenin (DIG)-labeled RNA probes and anti-DIG
alkaline phosphatase conjugated antibody as previously
described [50]. Transcription of three other zebrafish
claudins, claudin-h (GenBank: NM_131767), claudin-k
(GenBank: NM_001003464) and claudin-i (GenBank:
NM_131770), were also tested from 1 to 4 dpf.
Generation of Tg(l-fabp:DBP-EGFP) fish
The Tol2 transposon system [51,52] was used for trans-
genesis. A 3.5 kb promoter sequence of the l-fabp gene
[25] was amplified from genomic DNA of wild-type zeb-
rafish. The promoter was inserted into the ApaIa n d
BamHI sites of the pT2KXIGΔin vector [52] to replace
the EF-1a promoter. The coding sequence of zebrafish
DBP was amplified from a cDNA clone (GenBank:
BC076230) and inserted into the BamHI of pT2KXI-
GΔin to make an inframe fusion at the N terminus of
EGFP. Transposase RNA was transcribed in vitro from
the pCS-TP vector. Approximately 1 nl of an injection
solution, containing 25 ng/μl circular plasmid DNA and
25 ng/μl transposase RNA, was microinjected into 1- to
2-cell stage embryos as described [52]. EGFP expression
was examined by fluorescent microscopy (Nikon EFD-
3); embryos with expected expression patterns were
raised to establish the transgenic lines.
Confocal imaging
Live embryos/larvae or immunohistochemical samples
were mounted in 1% low-melting agarose. Confocal
images were acquired using a Leica DM IRBE inverted
microscope coupled to the Leica TCS-SP2 system using
a Plan-Apochromat 10×/0.40 lens. Green (for EGFP,
FD4 and fluorescein) and red (for mChery and Alexa
Fluor 568) channels were excited using an Agron/Krypton
and Helium/Neon laser, and emissions were detected
using filters set by the Leica Confocal Software.
Disrupting the BRB with bradykinin
Tg(l-fabp:DBP-EGFP) and Tg(flk1:mCherry) fish were
crossed to obtain embryos bearing double transgenes.
From 5 dpf, the larvae were bathed in embryo medium
[49] containing 0, 8, 20, 50 or 100 μMb r a d y k i n i n .A t9
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Page 12 of 14dpf, the larvae were mounted in 2% methylcellulose;
leakage of the DBP-EGFP out of the hyaloid vessels was
examined by fluorescent microscopy (Nikon EFD-3). Tg
(flk1:EGFP) larvae were also immunohistochemically
stained with anti-claudin-5 after treatment with 100 μM
bradykinin.
Additional material
Additional file 1: Expression of ZO-1 in the developing BRB and
BBB of zebrafish. Tg(flk1:EGFP) embryos at 2 dpf to 3 dpf were stained
with rabbit anti-ZO-1; confocal images were analyzed for ZO-1
expression (red) (A-G; Alexa Fluor 568) and blood vessels (green) (A’-E’;
EGFP). A&A’, lateral views; the other panels, dorsal views. (A&A’) The ZO-1
signal is high in the gut (shaded arrow) and low in the intersegmental
vessels (arrows). (B&B’) At 2 dpf, ZO-1 is localized to the HV (arrows) and
the HA (arrowheads). (C&C’) At 3 dpf, the HV (arrows), inner plexiform
layer (shaded arrowhead) as well as the outer limiting membrane
(shaded arrow) show a strong signal of ZO-1. (D&D’,E & E ’) At 2 dpf, most
brain vessels express ZO-1, including the BCA (arrowheads). Similar to the
claudin-5 antibody, the ZO-1 antibody binds to many non-endothelial
structures in the brain (shaded arrows and shaded arrowhead) besides
the brain vasculature (arrows). (F&G) At 2 dpf, the ZO-1 antibody can
stain the polygonal RPE cells (arrows) clearly. The insert in G is an
enlarged view of the dashed square. Scale bars: 50 um.
Additional file 2: In situ hybridization of cldn-5a, cldn-5b and
cldn-h. Wild type embryos at 2.5 dpf were probed with anti-sense
probes of cldn5a, cldn5b and cldn5h. The cldn-5a and cldn-5b had very
strong signal in the hyaloid vasculature around the lens, while the cldn-h
did not. Two sense controls did not show any signal.
Additional file 3: Claudin 5b is expressed in hyaloid vessels. A 5.6 kb
upstream sequence of claudin-5b can drive expression of EGFP in the
hyaloid vessels. The inset is an enlarged view of the green hyaloid
vessels.
Additional file 4: Bradykinin induces BRB breakdown. At 5 dpf, 20
double transgenic (l-fabp:DBP-EGFP;flk1:mCherry) larvae were injected with
2 uL of 20 uM bradykinin in the right eye (B, B’, C and C’). 3 hours after
injection, the BRB was found to be disrupted in 18 injected eyes, as
indicated by the leakage of DBP-EGFP (green) (B, C) from the hyaloid
vessels (red) (B’C’) which showed normal morphology. No leakage was
observed in any of the BSA injected contra-lateral negative control eyes
(A, A’).
Additional file 5: DBP-EFGP is a 78 kDa protein in l-fabp:DBP-EGFP
zebrafish. The expression level and molecular weight of DBP-EGFP was
analyzed by western blot analysis of lysates from l-fabp:DBP-EGFP (A) and
wild type (B) embryos using anti-GFP antibodies (Abcam, ab290). A 78
kDa protein was detected in lysates from transgenic embryos.
Additional file 6: Morpholino knockdown of claudin 5a in zebrafish
embryos results in BRB breakdown. Cldn-5a was knocked down by
injecting morpholino-cldn5a into double transgenic l-fabp:DBP-EGFP;flk1:
mCherry embryos at the 2-cell stage. At 4 dpf, leakage of DBP-EGFP
(green) from the hyaloid vasculature (red) was observed. A 5 bp-
mismatched Morpholino was injected as control and showed an intact
BRB.
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